Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
164 results
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan
000372 - A Case Report of Late-Onset Immunodeficiency: Good's Syndrome
001589 - Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)
100020 - Health Quality and Treatment Satisfaction in IEI Patients; Not only IgRT but Comorbidities
100457 - Use of subcutaneous human immunoglobulin in patients with hypogammaglobulinemia secondary to nephrotic syndrome in a tertiary pediatric hospital
100536 - Late onset immunodeficiency in children
D1.230 - Acute Localized Exanthemathous pustulosis induced by Pertuzumab and Trastuzumab with positive Lymphocyte Transformation test
D2.119 - Real-life experience in eosinophilic granulomatosis with polyangiitis (EGPA) after 12 months with mepolizumab 300mg in specialized autoimmune and asthma units in an Universitary Hospital
D2.343 - Use of IDDA 2.1 score in Common Variable Immunodeficiency (CVID): a single center experience
D2.344 - Unraveling the Mysteries of Chronic Granulomatous Disease: A Case of detected Protein Deficiency Amidst Negative Genetic Screening
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Page
7
Page
8
Page
9
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download